BRL 50481, >= 98%( HPLC ), solide

Code: b0936-25mg D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

BRL 50481 is a potent and selective PDE7 inhibitor (IC50 = 260 nM).

Features and Benefits

This compound was developed by ...


en savoir plus

Votre prix
£227.00 25MG
DEMANDER

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

BRL 50481 is a potent and selective PDE7 inhibitor (IC50 = 260 nM).

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Legal Information

Sold for research purposes under agreement from GlaxoSmithKline

Packaging

5, 25 mg in glass bottle

assay≥98% (HPLC)
colorwhite to off-white
formsolid
Gene Informationhuman ... PDE7A(5150), PDE7B(27115)
InChI keyIFIUFCJFLGCQPH-UHFFFAOYSA-N
InChI1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3
originatorGlaxoSmithKline
Quality Level100
SMILES stringCN(C)S(=O)(=O)c1cc(ccc1C)[N+]([O-])=O
solubilityDMSO: >10 mg/mL, H2O: insoluble
storage temp.2-8°C
Code
Description
Unité de vente
Prix annoncé
Qté
B0936-5MG
BRL 50481, >= 98%( HPLC ), solide

Unité:5MG
Prix annoncé: £75.10
Source:Prix annoncé
AJOUTER
Cas Number433695-36-4
Ce produit répond aux critères suivants: